Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  interleukin-2 gene
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, NIH WGMCC
Protocol IDs: 030162, 03-C-0162, NCI-5855, CDR0000304438, NCT00062036
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: U1111-1114-6557, NCT01176552
Phase I Study of Interleukin-2 Gene-Modified Autologous Tumor Cell Vaccine in Advanced Breast Cancer (Summary Last Modified 11/1999)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: DUMC-93122, NCI-H96-1111
Gene-Modified Cancer Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000582397, BCM-H-11541, BCM-CLIMAT, NCT00609076
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine
Phase: Phase I
Type: Treatment
Status: Completed
Age: 75 and under
Sponsor: Other
Protocol IDs: H6408-Leu Leu, NCT00058799
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: H11967, CLIPA, NCT00078520
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 19747-PRIMAL, PRIMAL, NCT00458679
Start Over